The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC).
Ghassan K. Abou-Alfa
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Jennifer Ma
No relevant relationships to disclose
Eileen Mary O'Reilly
Consultant or Advisory Role - Bayer (I)
Research Funding - Bayer (I)
Bolorsukh Gansukh
No relevant relationships to disclose
Joanne F. Chou
No relevant relationships to disclose
Marinela Capanu
No relevant relationships to disclose
Leonard Saltz
Research Funding - Bayer